Latest Chronic obstructive pulmonary disease Stories
Company to scale FDA-cleared digital therapeutic to tackle $100 billion cost of treating asthma and chronic obstructive pulmonary disease (COPD) MADISON, Wisc.
Sales of the LABA/LAMA Combination Drug Class are Expected to Grow Significantly Over the Next Six Months, According to Findings from Decision Resources Group BURLINGTON, Mass., Aug.
Despite Cost and Coverage Constraints, Physicians Manage to Prescribe LABA and LAMA Regimens in Combination for COPD, According to Findings from Decision Resources Group BURLINGTON, Mass.,
For U.S. Media Only RIDGEFIELD, Conn., Aug. 19, 2014 /PRNewswire/ -- Boehringer Ingelheim today announced that the U.S.
The microdevice can provide new insights in disease studies and drug discovery by mimicking the complex multicellular structure and function of human airway tissue. Research
Committee Voted Based on Clinical Data from Eight Efficacy Trials RIDGEFIELD, Conn., Aug. 14, 2014 /PRNewswire/ -- Boehringer Ingelheim Pharmaceuticals, Inc.
New site is filled with information, patient testimonials, easy-to-use tools and real-world tips for people affected by COPD RESEARCH TRIANGLE PARK, N.C., Aug.
New Study Published in The Lancet Respiratory Medicine is First to Provide Strong Evidence Supporting Long-term NPPV in the Treatment of COPD SAN DIEGO, Aug.
For U.S. Media Only RIDGEFIELD, Conn., Aug. 1, 2014 /PRNewswire/ -- Boehringer Ingelheim today announced that the U.S.
- To give a box on the ear to.